



0590  
1653

1653

Att. Docket No.: REG 753B

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Att. Docket No.: : REG 753B  
USSN : 10/061,043  
Applicant : GLASS, D and BODINE, S  
Date Filed : JANUARY 30, 2002  
For : NOVEL NUCLEIC ACIDS AND  
POLYPEPTIDE MOLECULE

RECEIVED  
MAR 19 2003  
TECH CENTER 1600/2900

**FIRST CLASS MAIL CERTIFICATE**

I hereby certify that this document is being deposited with the United States Postal Service on this date as first class mail addressed to: Commissioner for Patents, United States Patent and Trademark Office, Washington, D.C. 20231.

Bernadette B. Fahey  
Bernadette B. Fahey

March 11, 2003  
Date

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§ 1.56 and 1.97**

Assistant Comm. Patent and Trademarks  
Washington, D.C. 20231

RECEIVED  
APR 22 2003  
TECH CENTER 1600/2900

Dear Sir:

In compliance with the applicant's duty to submit information material to patentability of the above-referenced case, Applicants herein submit the following Information Disclosure Statement with the accompanying PTO Form 1449 and copies of references listed therein. The PTO is kindly requested to make of record those references which may be pertinent to the examination of the above-referenced application.

This Information Disclosure Statement is being filed:

- [X] (b) Within three months of the filing date of the above referenced application; within three months of the entry of an international application into the national phase; before the mailing date of a first Office action on the merits; or before the

mailing of a first Office action after the filing of a request for continued examination under § 1.114. Accordingly, no fee is required for the submission.

or

- ☐ (c) After (b) above, but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or any action that otherwise closes prosecution in the application. Accordingly, the undersigned certifies as follows:

☐ (e)(1) Each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the date of the filing of this IDS; or

☐ (e)(2) No item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing the certification after making reasonably inquiry, no item of information contain in the IDS was known to any individual designated in § 1.56(c) more than three months prior to the filing of this IDS;

or

- ☐ This IDS is accompanied by the fee set forth in 37 CFR § 1.17(p);

or

- ☐ (d) After (c) above, but on or before payment of the issue fee and the undersigned certifies as follows:

☐ (e)(1) Each item of information contained in this IDS was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the date of the filing of this IDS; or

☐ (e)(2) No item of information contained in this IDS was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the person signing the certification after making reasonably inquiry, no item of information contain in the IDS was known to any individual designated in § 1.56(c) more than three months prior to the filing of this IDS;

and

- ☐ This IDS is accompanied by the fee set forth in 37 CFR § 1.17(p).

### REQUEST FOR TRANSFER OF REFERENCE COPIES

[ ] Applicants respectfully request that the cited references filed in the Information Disclosure Statement submitted in connection with parent application USSN \_\_\_\_\_, filed \_\_\_\_\_, be transferred to the subject application for consideration by the Examiner

### Fees

The fee required for the filing of this Information Disclosure Statement is estimated to be \$\_\_\_\_\_. Applicants hereby authorize such charge to Deposit Account number 18-0650. If any additional fee should be deemed necessary, the Commissioner is hereby authorized to charge Deposit Account Number 18-050.

Respectfully submitted -

  
Laura J. Fischer

Reg. No. 50,420

Regeneron Pharmaceuticals, Inc.

777 Old Saw Mill River Road

Tarrytown, New York 10591

(914) 345-7400



FORM PTO-1449

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Att. Docket No.: : REG 753B  
USPN : 10/061,043  
Applicant : GLASS, D and BODINE, S  
Date Filed : JANUARY 30, 2002  
For : NOVEL NUCLEIC ACIDS AND  
POLYPEPTIDE MOLECULE

March 11, 2003

RECEIVED

MAR 19 2003

TECH CENTER 1600/2900

### U.S. PATENT DOCUMENTS

| Examiner<br>Initials | Patent<br>Number | Issue<br>Date | Publication<br>Number | Filing<br>Date | Name                 |
|----------------------|------------------|---------------|-----------------------|----------------|----------------------|
| _____                | 5,552,442        | 9/3/96        | 427663                | 4/24/95        | Maltin, Charlotte A. |

### FOREIGN PATENT DOCUMENTS

| Examiner<br>Initials | Document<br>Number | Filing<br>Date | Country | Class/<br>Subclass                  | Translation<br>Yes No |
|----------------------|--------------------|----------------|---------|-------------------------------------|-----------------------|
| _____                | WO 00/12679        | 8/27/99        | PCT     | C12N5/00<br>15/00<br>15/09<br>15/63 |                       |

### OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, etc.)

EXAMINER  
CONSIDERED

DATE

\_\_\_\_\_ Bodine, S. et al. Identification of Ubiquitin Ligases Required for Skeletal Muscle Atrophy. Science. 2001 294(5547): 1704 - 1708.

\_\_\_\_\_ Cenciarelli, C. et al. Identification of a family of human F-box proteins.  
Curr Bio. 1999. 9:1177 – 1179.

\_\_\_\_\_ Kamura, T. et al. Rbx1, a Component of the VHL Tumor Suppressor  
Complex and SCF Ubiquitin Ligase. 1999. Science. 284: 657 – 661.

\_\_\_\_\_ Gomes, M. et al. Atrogin-1, a muscle-specific F-box protein highly  
expressed during muscle atrophy. PNAS. Early Edition.  
2001 1 – 6.

\_\_\_\_\_ Patton, E. et al. Cdc53 is a scaffold protein for multiple Cdc34/Skp1/F-  
box protein complexes that regulate cell division and methionine  
biosynthesis in yeast. 1998. Genes & Dev. 12: 692 – 705.

\_\_\_\_\_ Skowyra, D. et al. F-box Proteins Are Receptors that Recruit  
Phosphorylated Substrates to the SCF Ubiquitin-Ligase Complex. 1997.  
Cell. 91:209 – 219

\_\_\_\_\_ Skowyra, D. Reconstitution of G1 Cyclin Ubiquitination with Complexes  
Containing SCF/Grr1 and Rbx1. 1999. Science. 284: 662 – 665.


\_\_\_\_\_ Winston, J. A family of mammalian F-box proteins. 1999. Curr. Bio.  
9:1180 – 1182.

EXAMINER:

Initial if citation considered, whether or not citation is in  
conformance with MPEP 609; draw line through citation if  
not in conformance and not considered. Include copy of  
this form with next communication to applicant.

Respectfully submitted,

By:

  
\_\_\_\_\_  
Laura J. Fischer  
Reg No. 50, 420  
Attorney for Applicants  
Regeneron Pharmaceuticals, Inc.  
777 Old Saw Mill River Road  
Tarrytown, New York 10591  
(914) 345-7400